2023
Coffee, adenosine, and the liver
Dranoff J. Coffee, adenosine, and the liver. Purinergic Signalling 2023, 20: 21-28. PMID: 37755557, PMCID: PMC10828332, DOI: 10.1007/s11302-023-09968-5.Peer-Reviewed Original ResearchCoffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects
Dranoff J. Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects. AJP Gastrointestinal And Liver Physiology 2023, 324: g419-g421. PMID: 36976807, DOI: 10.1152/ajpgi.00026.2023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLiver diseaseLiver-related mortalityChronic liver diseaseFatty liver diseasePositive health outcomesPrimary active ingredientCoffee consumptionEpidemiological studiesHealth outcomesAdenosine receptorsBiological plausibilityDiseaseActive ingredientsPatientsAntagonistMortalityRecent publicationsReceptors
2017
Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis
Dranoff JA. Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis. Gene Expression 2017, 18: 1-3. PMID: 28893365, PMCID: PMC5885142, DOI: 10.3727/105221617x15046391179559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2015
I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
Feld JJ, Lavoie ÉG, Fausther M, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015, 4: 95. PMID: 25977756, PMCID: PMC4416533, DOI: 10.12688/f1000research.6368.2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseSalutary effectsLiver diseaseLiver fibrosisHepatocellular carcinomaNovel pharmacologic treatmentsCoffee ingestionPharmacologic treatmentFibrosis pathogenesisObservational studyRegular ingestionCoffee consumptionEpidemiological dataPharmacological effectsCaffeine consumptionCirrhosisDecaffeinated coffeeCaffeine effectsEffector moleculesPatientsFibrosisPathogenesisDiseaseIngestionConsistent effectStrategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014
Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015, 62: 627-634. PMID: 25626988, PMCID: PMC4515973, DOI: 10.1002/hep.27720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClinical trial designTrial designLiver diseaseLiver fibrosisClinical trialsFuture clinical trial designChronic liver diseaseOff-target toxicityKey unmetPotential off-target toxicityAntifibrotic agentsNoninvasive markerAntifibrotic therapyAntifibrotic drugsPreclinical proofDrug trialsStudy groupRisk populationsPharmacological targetsTrialsExpert overviewFibrosisDiseaseEndpointAmerican AssociationI drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
Feld J, Lavoie É, Fausther M, Dranoff J. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015, 4: 95. DOI: 10.12688/f1000research.6368.1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseSalutary effectsLiver diseaseLiver fibrosisHepatocellular carcinomaNovel pharmacologic treatmentsCoffee ingestionPharmacologic treatmentFibrosis pathogenesisObservational studyRegular ingestionCoffee consumptionEpidemiological dataPharmacological effectsCaffeine consumptionCirrhosisDecaffeinated coffeeCaffeine effectsEffector moleculesPatientsFibrosisPathogenesisDiseaseIngestionConsistent effect
2010
Biliary Cirrhosis
Dranoff J. Biliary Cirrhosis. Molecular Pathology Library 2010, 5: 467-473. DOI: 10.1007/978-1-4419-7107-4_31.Peer-Reviewed Original Research